IMPORTANCE: Biomarkers that predict suicidal behavior, especially highly lethal behavior, are urgently needed. In cross-sectional studies, individuals with depression who attempt suicide have lower midbrain serotonin transporter binding potential compared with those who do not attempt suicide, and higher serotonin1A binding potential in the raphe nuclei (RN) is associated with greater lethality of past suicide attempts and suicidal intent and ideation. OBJECTIVES: To determine whether serotonin transporter binding potential in the lower midbrain predicts future suicide attempts and whether higher RN serotonin1A binding potential predicts future suicidal ideation and intent and lethality of future suicide attempts. DESIGN, SETTING, AND PARTICIPANTS: In this prospective 2-year observational study, a well-characterized cohort of 100 patients presenting for treatment of a major depressive episode of at least moderate severity underwent positron emission tomography using carbon 11-labeled N-(2-(1-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl))-N-(2-pyridyl)-cyclohexanecarboxamide ([11C]WAY-100635), a serotonin1A antagonist; a subset of 50 patients also underwent imaging with carbon 11-labeled 3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)- benzonitrile ([11C]DASB), a serotonin transporter radioligand. Imaging was performed at Columbia University Medical Center from May 3, 1999, to March 11, 2008. Follow-up was completed on May 28, 2010, and data were analyzed from August 1, 2013, to March 1, 2016. EXPOSURES: Patients were treated naturalistically in the community and followed up for 2 years with documentation of suicidal behavior, its lethality, and suicidal ideation and intent. MAIN OUTCOMES AND MEASURES: Suicide attempt or suicide. RESULTS: Of the 100 patients undergoing follow-up for more than 2 years (39 men; 61 women; mean [SD] age, 40.2 [11.2] years), 15 made suicide attempts, including 2 who died by suicide. Higher RN serotonin1A binding potential predicted more suicidal ideation at 3 (b = 0.02; t = 3.45; P = .001) and 12 (b = 0.02; t = 3.63; P = .001) months and greater lethality of subsequent suicidal behavior (b = 0.08; t = 2.89; P = .01). Exploratory analyses suggest that the serotonin1A binding potential of the insula (t = 2.41; P = .04), anterior cingulate (t = 2.27; P = .04), and dorsolateral prefrontal cortex (t = 2.44; P = .03) were also predictive of lethality. Contrary to our hypotheses, suicidal intent was not predicted by serotonin1A binding potential in any brain region (F1,10 = 0.83; P = .38), and midbrain serotonin transporter binding potential did not predict future attempts (log-rank χ21 = 0.4; P = .54), possibly owing to low power. CONCLUSIONS AND RELEVANCE: Greater RN serotonin1A binding potential predicted higher suicidal ideation and more lethal suicidal behavior during a 2-year period. This effect may be mediated through less serotonin neuron firing and release, which affects mood and suicidal ideation and thereby decision making.
IMPORTANCE: Biomarkers that predict suicidal behavior, especially highly lethal behavior, are urgently needed. In cross-sectional studies, individuals with depression who attempt suicide have lower midbrain serotonin transporter binding potential compared with those who do not attempt suicide, and higher serotonin1A binding potential in the raphe nuclei (RN) is associated with greater lethality of past suicide attempts and suicidal intent and ideation. OBJECTIVES: To determine whether serotonin transporter binding potential in the lower midbrain predicts future suicide attempts and whether higher RN serotonin1A binding potential predicts future suicidal ideation and intent and lethality of future suicide attempts. DESIGN, SETTING, AND PARTICIPANTS: In this prospective 2-year observational study, a well-characterized cohort of 100 patients presenting for treatment of a major depressive episode of at least moderate severity underwent positron emission tomography using carbon 11-labeled N-(2-(1-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl))-N-(2-pyridyl)-cyclohexanecarboxamide ([11C]WAY-100635), a serotonin1A antagonist; a subset of 50 patients also underwent imaging with carbon 11-labeled 3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)- benzonitrile ([11C]DASB), a serotonin transporter radioligand. Imaging was performed at Columbia University Medical Center from May 3, 1999, to March 11, 2008. Follow-up was completed on May 28, 2010, and data were analyzed from August 1, 2013, to March 1, 2016. EXPOSURES: Patients were treated naturalistically in the community and followed up for 2 years with documentation of suicidal behavior, its lethality, and suicidal ideation and intent. MAIN OUTCOMES AND MEASURES: Suicide attempt or suicide. RESULTS: Of the 100 patients undergoing follow-up for more than 2 years (39 men; 61 women; mean [SD] age, 40.2 [11.2] years), 15 made suicide attempts, including 2 who died by suicide. Higher RN serotonin1A binding potential predicted more suicidal ideation at 3 (b = 0.02; t = 3.45; P = .001) and 12 (b = 0.02; t = 3.63; P = .001) months and greater lethality of subsequent suicidal behavior (b = 0.08; t = 2.89; P = .01). Exploratory analyses suggest that the serotonin1A binding potential of the insula (t = 2.41; P = .04), anterior cingulate (t = 2.27; P = .04), and dorsolateral prefrontal cortex (t = 2.44; P = .03) were also predictive of lethality. Contrary to our hypotheses, suicidal intent was not predicted by serotonin1A binding potential in any brain region (F1,10 = 0.83; P = .38), and midbrain serotonin transporter binding potential did not predict future attempts (log-rank χ21 = 0.4; P = .54), possibly owing to low power. CONCLUSIONS AND RELEVANCE: Greater RN serotonin1A binding potential predicted higher suicidal ideation and more lethal suicidal behavior during a 2-year period. This effect may be mediated through less serotonin neuron firing and release, which affects mood and suicidal ideation and thereby decision making.
Authors: Ramin V Parsey; Maria A Oquendo; Norman R Simpson; R Todd Ogden; Ronald Van Heertum; Victoria Arango; J John Mann Journal: Brain Res Date: 2002-11-08 Impact factor: 3.252
Authors: R V Parsey; M Slifstein; D R Hwang; A Abi-Dargham; N Simpson; O Mawlawi; N N Guo; R Van Heertum; J J Mann; M Laruelle Journal: J Cereb Blood Flow Metab Date: 2000-07 Impact factor: 6.200
Authors: E Baca-García; C Diaz-Sastre; E Basurte; R Prieto; A Ceverino; J Saiz-Ruiz; J de Leon Journal: J Clin Psychiatry Date: 2001-07 Impact factor: 4.384
Authors: Maria A Oquendo; Giovanni P A Placidi; Kevin M Malone; Carl Campbell; John Keilp; Beth Brodsky; Lawrence S Kegeles; Thomas B Cooper; Ramin V Parsey; Ronald L van Heertum; J John Mann Journal: Arch Gen Psychiatry Date: 2003-01
Authors: Jessica R Gilbert; Elizabeth D Ballard; Christina S Galiano; Allison C Nugent; Carlos A Zarate Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2019-12-03
Authors: Elizabeth T Cox Lippard; Jennifer A Y Johnston; Linda Spencer; Susan Quatrano; Siyan Fan; Anjali Sankar; Judah Weathers; Brian Pittman; Maria A Oquendo; Hilary P Blumberg Journal: J Affect Disord Date: 2018-11-28 Impact factor: 4.839
Authors: Elizabeth D Ballard; Sam L Snider; Allison C Nugent; David A Luckenbaugh; Lawrence Park; Carlos A Zarate Journal: Psychiatry Res Date: 2017-07-31 Impact factor: 3.222
Authors: Manesh Gopaldas; Francesca Zanderigo; Serena Zhan; R Todd Ogden; Jeffrey M Miller; Harry Rubin-Falcone; Thomas B Cooper; Maria A Oquendo; Gregory Sullivan; J John Mann; M Elizabeth Sublette Journal: J Affect Disord Date: 2019-07-05 Impact factor: 4.839
Authors: Elizabeth A Bartlett; Francesca Zanderigo; Denise Shieh; Jeffrey Miller; Patrick Hurley; Harry Rubin-Falcone; Maria A Oquendo; M Elizabeth Sublette; R Todd Ogden; J John Mann Journal: Mol Psychiatry Date: 2022-04-29 Impact factor: 13.437
Authors: Murray B Stein; Erin B Ware; Colter Mitchell; Chia-Yen Chen; Susan Borja; Tianxi Cai; Catherine L Dempsey; Carol S Fullerton; Joel Gelernter; Steven G Heeringa; Sonia Jain; Ronald C Kessler; James A Naifeh; Matthew K Nock; Stephan Ripke; Xiaoying Sun; Jean C Beckham; Nathan A Kimbrel; Robert J Ursano; Jordan W Smoller Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2017-09-13 Impact factor: 3.568
Authors: C Elise Kleyn; Peter S Talbot; Nehal N Mehta; Francesca Sampogna; Chris Bundy; Darren M Ashcroft; Alexa B Kimball; Peter C M van de Kerkhof; Christopher E M Griffiths; Fernando Valenzuela; Joelle M van der Walt; Tsion Aberra; Lluís Puig Journal: Acta Derm Venereol Date: 2020-01-07 Impact factor: 3.875